<DOC>
	<DOCNO>NCT00038571</DOCNO>
	<brief_summary>Purpose Phase II study B-cell lymphoma use PS341 : Evaluate efficacy toxicity bortezomib patient relapse refractory B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Proteasome Inhibitor PS-341 Relapsed Refractory B Cell Lymphomas Previously Treated With Chemotherapy</brief_title>
	<detailed_description>Patients stratify , base preclinical data , arm A ( mantle-cell lymphoma ) arm B ( B-cell lymphoma ) without limitation number prior therapy . Bortezomib administer intravenous push ( 1.5 mg/m2 ) day 1 , 4 , 8 , 11 every 21 day maximum six cycle .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>INCLUSION : Relapsed Refractory B cell lymphoma . Zubrod status &lt; /= 3 . Measurable disease . No anticancer treatment within past 3 week . ANC &gt; = 1500/uL , Plt &gt; /= 50,000 , Bilirubin &lt; 2 mg/dL , SGPT &lt; 2.5xULN , creatinine &lt; 2 . Patients ANC &gt; /1000 , PLT &gt; /30000 eligible due massive splenomegaly and/or BM involvement . HIV negative . No active CNS lymphoma . No serious intercurrent illness , active infection cancer except basal cell carcinoma skin situ cervical carcinoma . Not eligible treatment high priority . Patients may enter BMT . No pregnancy &amp; age bearing female must practice adequate contraception . Age &gt; 16 . EXCLUSION : Patients platelet &lt; 30x10 ( 9 ) /L within 14 day enrollment . Patients ANC &lt; 1.0 x10 ( 9 ) /L within 14 day enrollment . Patients peripheral neuropathy &gt; /= grade 3 within 14 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>B cell lymphoma</keyword>
	<keyword>Proteasome Inhibitor</keyword>
	<keyword>PS-341</keyword>
</DOC>